Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

被引：0
|
作者：
Takeru Shiroiwa
Takashi Fukuda
Kojiro Shimozuma
Mitsuko Mouri
Yasuhiro Hagiwara
Takuya Kawahara
Shozo Ohsumi
Yasuo Hozumi
Yoshiaki Sagara
Yasuo Ohashi
Hirofumi Mukai
机构：
[1] Department of Health and Welfare Services,Department of Biomedical Sciences, College of Life Sciences
[2] National Institute of Public Health,Department of Biostatistics, School of Public Health
[3] Ritsumeikan University,Biostatistics Division, Clinical Research Support Center
[4] Kanagawa Academy of Science and Technology (KAST),Department of Breast and Endocrine Surgery
[5] The University of Tokyo,Department of Integrated Science and Engineering
[6] The University of Tokyo Hospital,undefined
[7] Department of Breast Oncology,undefined
[8] National Hospital Organization Shikoku Cancer Center,undefined
[9] University of Tsukuba Hospital,undefined
[10] Department of Breast Surgery,undefined
[11] Ibaraki Prefectural Central Hospital,undefined
[12] Breast Surgery Department,undefined
[13] Social Medical Corporation Hakuaikai Sagara Hospital,undefined
[14] Chuo University,undefined
[15] Division of Breast and Medical Oncology,undefined
[16] National Cancer Center Hospital East,undefined
来源：
BMC Cancer | / 17卷
关键词：
Cost-effectiveness analysis; Quality-adjusted life years; Breast neoplasms; Randomized controlled trial; S-1; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, AND METASTATIC CERVICAL CANCER IN THE UNITED STATES: RESULTS FROM THE FINAL ANALYSIS OF TRIAL
    Swami, S.
    Hale, O.
    Thornton, I
    Muston, D.
    Monberg, M. J.
    Monk, B. J.
    VALUE IN HEALTH, 2023, 26 (12) : S183 - S183
  • [22] Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
    Kwakman, J. J.
    Van Werkhoven, E.
    Simkens, L. H.
    van Rooijen, J. M.
    van de Wouw, A.
    Ten Tije, A. J.
    Creemers, G-J.
    Hendriks, M. P.
    Los, M.
    van Alphen, R.
    Polee, M. B.
    Muller, E. W.
    Van der Velden, A.
    Van Voorthuizen, T.
    Koopman, M.
    Mol, L.
    Punt, C. J. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study
    Takashima, Tsutomu
    Hara, Fumikata
    Iwamoto, Takayuki
    Uemura, Yukari
    Ohsumi, Shozo
    Yotsumoto, Daisuke
    Hozumi, Yasuo
    Watanabe, Takanori
    Saito, Tsuyoshi
    Watanabe, Ken-ichi
    Tsurutani, Junji
    Toyama, Tatsuya
    Akabane, Hiromitsu
    Nishimura, Reiki
    Taira, Naruto
    Ohashi, Yasuo
    Mukai, Hirofumi
    CLINICAL BREAST CANCER, 2021, 21 (05) : 450 - 457
  • [24] Combined analysis of three randomized phase III trials comparing S-1 monotherapy and S-1 combination therapy for first-line treatment of advanced gastric cancer.
    Takeuchi, Madoka
    Ichikawa, Wataru
    Shitara, Kohei
    Sunakawa, Yu
    Oba, Koji
    Michimae, Hirofumi
    Saad, Everardo D.
    Koizumi, Wasaburo
    Sakata, Yuh
    Furukawa, Hiroshi
    Buyse, Marc E.
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
    Strumberg, D.
    Bergmann, L.
    Graeven, U.
    Hanauske, A.
    Lipp, R.
    Schuette, J.
    Schultheis, B.
    Scigalla, P.
    Urrea, P.
    Scheulen, M. E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (07) : 470 - 472
  • [27] S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Koizumi, Wasaburo
    Narahara, Hiroyuki
    Hara, Takuo
    Takagane, Akinori
    Akiya, Toshikazu
    Takagi, Masakazu
    Miyashita, Kosei
    Nishizaki, Takashi
    Kobayashi, Osamu
    Takiyama, Wataru
    Toh, Yasushi
    Nagaie, Takashi
    Takagi, Seiichi
    Yamamura, Yoshitaka
    Yanaoka, Kimihiko
    Orita, Hiroyuki
    Takeuchi, Masahiro
    LANCET ONCOLOGY, 2008, 9 (03): : 215 - 221
  • [28] Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer -: Results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 randomized trial
    Borget, Isabelle
    Auperin, Anne
    Pignon, Jean-Pierre
    Abbas, Moncef
    Bouche, Olivier
    Mousseau, Mireille
    Raoul, Jean-Luc
    Bedenne, Laurent
    Cassan, Philippe
    Clavero-Fabri, Marie-Christine
    Stremsdoerfer, Noel
    Nasca, Salvador
    Queuniet, Anne-Marie
    Ducreux, Michel
    ONCOLOGY, 2006, 71 (1-2) : 40 - 48
  • [29] A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients
    Yamamoto, D.
    Iwase, S.
    Odagiri, H.
    Kuroda, Y.
    Akazawa, K.
    Kitamura, K.
    Kawaguchi, T.
    Yamamoto, C.
    Nagumo, Y.
    Sakata, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] IMPACTS OF ADVERSE EVENTS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS RECEIVING FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER: RESULTS FROM RANDOMIZED PHASE III SELECT BC STUDY
    Hagiwara, Y.
    Shimozuma, K.
    Shiroiwa, T.
    Kawahara, T.
    Uemura, Y.
    Watanabe, T.
    Taira, N.
    Fukuda, T.
    Ohashi, Y.
    Mukai, H.
    VALUE IN HEALTH, 2016, 19 (07) : A745 - A745
12345